49 results about "Programmed cell death" patented technology

Disclosed are a method, a device, and an information processing program for determining, by using refractive index distribution data pertaining to an object to be observed, the region of a cell that has undergone programmed cell death in the object to be observed.

The invention relates to tilletia foetida, in particular to a tilletia foetida effect protein TlRlpA and application thereof. The invention provides a Tilletia foetida effect protein, and the amino acid sequence of the Tilletia foetida effect protein is shown as SEQ ID NO: 2, SEQ ID NO: 4 or SEQ ID NO: 6. The effector protein can effectively inhibit programmed death of plant cells induced by BAX, and plays an important role in inhibiting a plant defense reaction process. The invention lays a foundation for deeply researching the pathogenesis of the tilletia foetida, excavating the tilletia foetida-resistant gene of the wheat and developing the tilletia foetida-resistant wheat variety.

The present application provides antibodies including antigen binding fragment thereof that specifically recognizing programmed cell death 1 ligand 1 (PD-L1). Also provided are methods of making and using these antibodies.

Provided herein are binding molecules that bind to programmed cell death protein 1 (PD-1). Such binding molecules block the interaction between PD-1 and programmed death-ligand 1 and 2 (PD-L1 and PD-L2). Also provided herein are methods of using such binding molecules for preventing and treating cancer.

Provided is the use of a genetically engineered phage expressing a first peptide targeting a Programmed Cell Death protein 1 (PD-1) or Programmed Cell Death-Ligand 1 (PD-L1) and a second peptide targeting a cancer-related antigen for enhanced efficacy in cancer treatment. Thus, provided are methods for improved anti-cancer therapy, especially in the treatment of solid tumors, by using a recombinant phage that is capable of specifically targeting the PD-1 / PD-L1 pathway and specifically targeting a cancer antigen, as well as compositions and kits useful for such treatment methods.

This disclosure describes an artificial expression construct containing a PD1:cytokine chimeric transgene under the control of an inducible promoter. The artificial expression construct of this disclosure can be used to enhance the function of immune cells (e.g., CAR-T cells) that have recombinant receptors. The inducible PD1:cytokine chimeric transgene disclosed herein enhances the potency of immune cells (e.g., CAR-T cells) that have recombinant receptors, thereby enhancing killing, proliferation of immune cells, and / or cytokine production.

The invention discloses a rice disease resistance defense regulation gene SRWD2 as well as an encoding protein and application thereof. According to the invention, a rice disease spot-like mutant tb18 is taken as an experimental material, a rice disease resistance defense regulation gene SRWD2 is separated through strategies such as MutMap positioning and transgene complementation, the nucleotide sequence of the gene is shown as SEQ ID NO.1, and the sequence of a protein coded by the gene is shown as SEQ ID NO.2. The biological function of the SRWD2 gene is analyzed, a theoretical basis is provided for clarification of a molecular mechanism of programmed cell death and defense reaction of plants, the gene mutation site is introduced into the plants through gene engineering or conventional means, the disease resistance can be remarkably enhanced, and the gene has important application value in the aspect of disease-resistant variety cultivation of the plants.

Exemplary methods, compositions, kits and uses thereof for treating neoplasia are provided. For example, a method can be provided for treating neoplasia in a subject, including administering to the subject a VRK2 (vaccinia-related kinase 2) inhibitor, alone or in combination with an inhibitor of Programmed cell death receptor-1 (PD-1). The exemplary methods, compositions and kits may improve cancer immunotherapy.

Targeting immune checkpoints, such as Programmed cell Death 1 (PD1), has improved survival in cancer patients by unleashing exhausted CD8+ T-cell thereby restoring anti-tumor immune responses. Most patients, however, relapse or are refractory to immune checkpoint blocking therapies. Here, the inventors show that NRP1 is recruited in the cytolytic synapse of PD1+CD8+ T-cells, interacts and enhances PD-1 activity. In mice, CD8+ T-cell specific deletion of Nrp1 improves spontaneous and anti PD1 antibody anti-tumor immune responses. Likewise, in human metastatic melanoma, the expression of NRP1 in tumor infiltrating CD8+ T-cells predicts poor outcome of patients treated with anti-PD1 (e.g. pembrolizumab). Finally, the combination of anti-NRP1 and anti-PD1 antibodies is synergistic in human, specifically in CD8+ T-cells anti-tumor response. Thus the therapeutic inhibition of NRP1 alone or combined with an immune checkpoint inhibitor (e.g. anti-PD1 antibody) could efficiently repress tumor growth in human cancer. The present invention also relates to multispecific antibodies comprising at least one binding site that specifically binds to an immune checkpoint molecule (e.g. PD-1), and at least one binding site that specifically binds to NRP-1. The present invention also relates to a population of cells engineered to express a chimeric antigen receptor (CAR) and wherein the expression of NRP-1 in said cells is repressed.

The disclosure provides amino acid sequence variants of programmed cell death protein 1 (PD-1) that can bind to either or both of its ligands, PDL-1 or PDL-2. The disclosure relates to ligand-binding fragments of the PD-1 variant sequences, conjugates, and related compositions and formulations. The disclosure also relates to methods for using the sequences, e.g., PD-1 variants and ligand-binding fragments thereof, in the treatment of checkpoint pathway-related diseases, disorders, and conditions including cell proliferative diseases such as cancer, as well as diseases, disorders, and conditions associated with immune deficiency, immune insufficiency, and / or subjects who are immune compromised.

The invention discloses a DNA polymerase theta (Pol theta) and programmed cell death-ligand 1 (PD-L1) double-target inhibitor as well as a preparation method and medical application of the DNA polymerase theta (Pol theta) and programmed cell death-ligand 1 (PD-L1) double-target inhibitor. The compound disclosed by the invention is shown as a general formula (I), can target Pol theta and PD-L1 at the same time, plays a dual role in inhibiting the Pol theta and the PD-L1, and can be used for preparing a medicine for treating homologous recombination repair (HR) defect type cancers. (I).

The present invention provides a means or the like capable of temporarily inhibiting expression of PD-1 or CTLA-4 protein. The present invention relates to an antisense oligonucleotide or the like capable of hybridizing with a nucleic acid sequence of an mRNA precursor and / or mature mRNA of Programmed Cell Death 1 (PD-1) protein or Cytotoxic T-lymphocyte Antigen-4 (CTLA-4) protein and suppressing or inhibiting the expression of PD-1 protein or CTLA-4 protein.

Disclosed herein is a composition for enhancing an abscopal effect of radiation, including a lymphocyte activation gene-3 (LAG-3) inhibitor and a programmed cell death protein-1 (PD-1) inhibitor. One aspect relates to a method of enhancing an abscopal effect of radiation by co-administering a composition including an LAG-3 inhibitor and a PD-1 inhibitor in conjunction with radiotherapy in the treatment of cancer (e.g., triple-negative breast cancer).

The present invention relates to 1,2,4-oxadiazole and thiadiazole compounds of formula (I). The present invention also relates to the use of the compounds of formula (I) to inhibit the programmed cell death 1 (PD1) signaling pathway and / or for treatment of disorders by inhibiting an immunosuppressive signal induced by PD-1, PD-L1 or PD-L2.

This invention discloses a prognostic model and construction method for cervical squamous cell carcinoma, belonging to the fields of bioinformatics and oncology. The construction method is based on a set of genes related to programmed cell death, integrating multi-omics data of cervical squamous cell carcinoma patients from The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), and the Cancer Genome Characterization Project (CGCI). After standardized preprocessing, differential expression analysis, bootstrap resampling combined with univariate Cox regression for initial screening, consensus screening using multiple machine learning algorithms, and finally, multivariate Cox proportional hazards regression analysis to identify three core independent prognostic genes and construct a risk scoring model. This model has undergone multi-dimensional validation and optimization, demonstrating robust predictive performance. The method of this invention is standardized and highly reproducible, and the constructed model has high accuracy and strong generalization ability, providing a reliable tool for individualized prognostic assessment and clinical decision-making for cervical squamous cell carcinoma patients.

Provided herein are binding molecules that bind to programmed cell death protein 1 (PD-1). Such binding molecules block the interaction between PD-1 and programmed death-ligand 1 and 2 (PD-L1 and PD-L2). Also provided herein are methods of using such binding molecules for preventing and treating cancer.

A combined pharmaceutical composition of sorbitol and a programmed cell death protein (PD)-1 inhibitor, as an anti-tumor combined pharmaceutical composition, includes sorbitol and a PD-1 inhibitor. The pharmaceutical composition is applied in the preparation of anti-tumor products. In the present disclosure, it is found for the first time that sorbitol has the indication of enhancing tumor immunotherapy, and sorbitol can be used in tumor immunotherapy to improve the survival and prognosis of tumor patients. Sorbitol combined with the PD-1 inhibitors can effectively kill tumor cells, which greatly improves the therapeutic effect of sorbitol compared with PD-1 inhibitors alone.

The invention relates to the field of application of radix aconiti carmichaeli polysaccharide, and provides novel application of radix aconiti carmichaeli polysaccharide, namely application of radix aconiti carmichaeli polysaccharide in preparation of medicine for treating rheumatoid arthritis. The method comprises the following steps: firstly, culturing MH7A cells in vitro, inducing the MH7A cells through monkshood polysaccharides with different concentrations, and systematically evaluating the regulation effect of the monkshood polysaccharides on the proliferation kinetics and apoptosis rate of the MH7A cells by adopting a cell activity detection kit and combining a flow cytometry analysis technology; it is proved that monkshood polysaccharides with different concentrations can inhibit MH7A cell proliferation and trigger a programmed cell death mechanism, and the monkshood polysaccharides are concentration-dependent. By dynamically monitoring the content of ROS in cells, the monkshood polysaccharide is found to be capable of reducing accumulation of ROS in MH7A cells. In addition, the phosphorylation modification level of NF-kB / P65 protein in MH7A cells and the expression level of TNF-alpha are measured through methods such as a Western Blot method and an ELISA method, and it is also proved that the monkshood polysaccharide can down-regulate the expression of the NF-kB / P65 protein and the TNF-alpha in the MH7A cells. In general, experimental results show that the monkshood polysaccharide has a strong anti-inflammatory effect on MH7A cells.

This invention discloses the effector protein *PpiniAvh17* from *Phytophthora indicum*, its encoding gene, and its applications, belonging to the field of molecular biology. The amino acid sequence of this protein is shown in SEQ ID NO.1. Experiments have demonstrated that this protein can effectively inhibit programmed cell death (PCD) induced by pathogen effector proteins (such as *Phytophthora indicum* INF1) and can promote *Phytophthora capsici* infection in plants, indicating that it functions as a toxic effector to suppress plant immunity. This invention also provides the gene encoding this protein (SEQ ID NO.2). This protein and its encoding gene can be used to prepare products that regulate plant cell death, enhance plant stress resistance, or study plant-pathogen interaction mechanisms, providing new molecular targets and tools for plant disease control.

The present disclosure relates to genetically modified T cells or chimeric antigen receptor (CAR) T cells, comprising genetic modifications that inhibit or inactivate the expression of prolyl 4 hydroxylase subunit alpha 1 (P4HA1) and / or programmed cell death 1 (PD1) in the T cells or CAR T cells. The present disclosure also relates to methods of treating cancer comprising administration of the modified T cells or CAR T cells as disclosed herein; or administration of P4HA1 inhibitors and / or PD1 / PD-1L inhibitors.

The application provides a lung adenocarcinoma prognosis marker and model, a lung adenocarcinoma prognosis model based on programmed cell death (PCD) related mRNA and lncRNA is constructed, and the biological function of the lncRNA model in lung adenocarcinoma is explored through bioinformatics analysis and experiments. The prognosis model covers all PCD pathways and various molecules, has a robust prognosis prediction accuracy, and can provide potential molecular targets for personalized treatment. The method of the application comprehensively constructs a lung adenocarcinoma diagnosis model suitable for Chinese population by using PCD related mRNA and lncRNA, enhances the recognition ability of tumor patient classification from multiple aspects, improves the accuracy and reliability of prognosis prediction, can provide strong support for promoting the personalized treatment strategy of lung adenocarcinoma patients, and is suitable for popularization and application.

The application discloses a nano material for targeting and driving resuscitation of dying cells, and a preparation method and application thereof. The nano material is a nano platelet vesicle with phosphatidylserine exposed to the outer layer of the membrane after nanoization and centrifugal treatment. The material is obtained by separating and enriching platelets from peripheral blood, then nanoizing the platelets, and then inducing the phosphatidylserine on the platelet membrane to evert through high-speed centrifugation. The material is used for preparing a medicine for promoting tissue repair, and the medicine promotes resuscitation of dying cells by targeting the dying cells and enhancing the membrane repair capacity of the dying cells, so as to promote tissue repair, including repair of orthopedic, muscle, skin, spinal cord or visceral tissue, especially repair of diabetic foot, skin avulsion injury, ischemic skin flap or spinal cord injury. The resuscitation of dying cells is promoted successfully without intervention of lysis programmed cell death initiation, so that the problems of off-target effect and treatment paradox existing in current mainstream small molecule inhibitor strategy are effectively solved.

Described herein are bicyclic peptides which are high affinity binders of programmed cell death 1 ligand 1 (PD-L1). Also provided are drug conjugates comprising the peptides described herein conjugated to one or more effector and / or functional groups. Also provided are pharmaceutical compositions comprising the peptides and drug conjugates described herein, and methods of using the peptide ligands and drug conjugates described herein for treating diseases mediated by PD-L1.

Combined preparations, and pharmaceutical compositions, comprising: (a) LAG-3 protein, or a derivative thereof that is able to bind to MHC class II molecules; and (b) a programmed cell death protein-1 (PD-1) pathway inhibitor, are described. The PD-1 pathway inhibitor, such as an anti-PD-1 antibody or an anti-PD-L1 antibody, and a soluble derivative of LAG-3, acting as an APC activator, together synergistically activate T cells (in particular, CD8+ T cells). Use of the combined preparations and compositions as medicaments, in particular for the treatment of cancer or infection, and to methods for the treatment of cancer or infection, is described.

The present invention relates to new anti-PD-1 (Programmed cell death 1) antibodies and antigen-binding fragments thereof for therapeutic and diagnostic methods and compositions using them.

Kits for combination therapy are provided.SOLUTION: Provided is a kit for combination therapy comprising an anti-IL-2 antibody or a pharmaceutical composition comprising the same, IL-2 or a pharmaceutical composition comprising the same, and an immune checkpoint inhibitor or a pharmaceutical composition comprising the same. The immune checkpoint inhibitor is a programmed cell death ligand 1 (PDL-1) checkpoint inhibitor, or a programmed cell death protein 1 (PD-1), optionally, the PDL-1 checkpoint inhibitor is selected from avelumab, atezolizumab, durvalumab, segmariumab, and enbufolimab, and the PD-1 checkpoint inhibitor is selected from nivolumab, pembrolizumab, cemiplimab, camrelizumab, zingeberilumab, tislelizumab, sintilimab, teriplizumab, prologolimab, penprimumab and the like.SELECTED DRAWING: Figure 1

The application belongs to the field of bioinformatics and relates to a neurodegenerative disease classification system based on biological big data. The application aims to solve the problem of poor classification accuracy and reliability of existing big data analysis tools for neurodegenerative diseases. The neurodegenerative disease classification system based on biological big data comprises a data acquisition module, a programmed cell death lncRNA scoring module, an lncRNA and programmed cell death correlation evaluation module, a programmed cell death gene optimization module, a random forest classifier module, and a to-be-tested module. The random forest classifier module is used to obtain a trained random forest classifier based on the mRNA significantly related to programmed cell death obtained by the programmed cell death gene optimization module. The to-be-tested module is used to classify the mRNA data of a to-be-tested neurodegenerative disease based on the trained random forest classifier.

Method and compositions for treating glioblastoma (GBM) and other cancers is disclosed, involving the combination of radiation therapy (RT), fatty acid synthase (FASN) inhibitors, and programmed cell death protein 1 (PD-1) inhibitors or programmed death ligand 1 (PD-L1) inhibitors. The disclosed approach addresses the technical problem of RT-induced immunosuppression and resistance in cancers by targeting RT-induced lipid metabolism, which promotes immune escape. FASN inhibitors block fatty acid synthesis, enhancing immune cell infiltration and restoring anti-tumor immunity. PD-1 / PD-L1 inhibitors further counteract immunosuppressive pathways to improve therapeutic efficacy. This combination therapy prolongs survival, induces immune memory, and is applicable to other cancers, including those exhibiting increased lipid content post-RT or chemotherapy, including melanoma, breast cancer, and lung cancer.

The invention discloses a phytophthora pini effector protein PpinAvh23 as well as a coding gene and application thereof, and belongs to the technical field of molecular biology. The amino acid sequence of the protein is as shown in SEQ ID NO. 1. Experiments show that the protein can specifically inhibit programmed death of plant cells induced by pathogenic bacteria elicitors, and it is proved that the protein can promote pathogen infection as a toxic effector in plants. The invention also provides a gene (SEQ ID NO.2) for coding the protein. The protein and the coding gene thereof can be used as a key molecular tool and a screening target for researching a plant-pathogen interaction mechanism, and a basis is provided for developing a new strategy for preventing and controlling plant diseases.

This invention discloses a molecular marker for programmed cell death protein in Litopenaeus vannamei and its application. The molecular marker includes molecular marker A, molecular marker B, molecular marker C, and molecular marker D located on the 6-like gene sequence of the programmed cell death protein in Litopenaeus vannamei. This invention utilizes these molecular markers as functional markers for Litopenaeus vannamei's resistance to Vibrio parahaemolyticus, thereby improving the disease resistance breeding of Litopenaeus vannamei. Specifically, genomic DNA is extracted from the muscle tissue of the Litopenaeus vannamei to be tested, and then used as template DNA for PCR amplification and purification of the PCR amplification products. The obtained products are then sequenced to determine the genotypes of molecular markers A, B, C, and D, thereby selecting individuals with superior genotypes for Litopenaeus vannamei breeding, promoting the research and application of disease-resistant aquaculture of Litopenaeus vannamei.